Fatty Liver (MASLD) in Canada: Guide & Reversal
Fatty liver disease — now officially called MASLD (metabolic dysfunction–associated steatotic liver disease) following a 2023 multi-society nomenclature update — affects an estimated one in four Canadian adults, making it the most common liver condition in the country. In most people at early stages, there are no symptoms; the condition is typically found on routine bloodwork or imaging. The underlying driver is insulin resistance and metabolic syndrome, not alcohol. The most evidence-backed treatment is lifestyle-first: a sustained 7–10% body-weight reduction reverses steatosis in 70–90% of patients, per the Vilar-Gomez trial (Gastroenterology, 2015), and the AASLD 2023 Practice Guidance places Mediterranean-pattern diet and targeted weight loss at the centre of management. For a detailed look at long-term prognosis by fibrosis stage, see our guide to fatty liver life expectancy.
What fatty liver disease is — and why the name changed in 2023
Fatty liver disease is the accumulation of excess fat inside liver cells, beyond the small amount that is normal. What has changed recently is how medicine labels and frames it.
In 2023, a major international Delphi consensus, involving more than 200 experts and published in Hepatology, replaced the older NAFLD/NASH terminology with MASLD (metabolic dysfunction–associated steatotic liver disease) and MASH (metabolic dysfunction–associated steatohepatitis). The reason: the old name defined the disease by what it was not (non-alcoholic), which obscured what was actually driving it. The new name anchors the diagnosis to the root cause, metabolic dysfunction, specifically insulin resistance and its downstream consequences.
For patients, this matters because it reframes where clinical attention should go. Treating MASLD is not primarily about the liver. It is about treating the metabolic environment that is damaging the liver — weight, blood sugar, lipids, blood pressure, and physical activity.
The Canadian Liver Foundation estimates that approximately one in four Canadian adults has some degree of fatty liver, the majority of whom are unaware of it. MASLD sits at the intersection of two of Canada's most pressing public health challenges: obesity and type 2 diabetes.
Take the free 3-minute eligibility quiz
Symptoms — and the asymptomatic reality of early stages
The most important thing to understand about fatty liver disease is that the majority of people at early stages have no symptoms at all. This is not a condition that usually announces itself with pain or obvious warning signs until significant damage has accumulated.
When symptoms do occur, they tend to emerge at more advanced stages and may include:
- Fatigue that is persistent and disproportionate to activity level
- A dull ache or discomfort in the upper right abdomen, where the liver sits beneath the rib cage
- Mild nausea, particularly after fatty meals
- Enlarged liver (hepatomegaly), which a clinician may detect on physical examination
At the stage of advanced fibrosis or cirrhosis, more serious signs can appear: jaundice (yellowing of the skin and whites of the eyes), swelling in the abdomen (ascites), easy bruising, and confusion. These represent significantly advanced disease and require urgent specialist assessment.
Because early MASLD is largely silent, diagnosis almost always comes through incidental discovery — either a routine blood panel showing mildly elevated liver enzymes, or an abdominal ultrasound ordered for another reason. Anyone with metabolic risk factors (abdominal weight, type 2 diabetes, prediabetes, elevated triglycerides, low HDL) should ask their family physician whether their annual bloodwork includes liver markers.
Causes — insulin resistance, metabolic syndrome, and diet
MASLD is a disease of metabolic dysfunction. The core causes are:
Insulin resistance is the central driver. When cells become less responsive to insulin, the liver is exposed to high levels of circulating insulin and glucose, and it responds by converting excess carbohydrates into fat and storing it within liver cells. The insulin resistance–fatty liver connection is one of the most well-established causal links in hepatology. This is why MASLD clusters so tightly with type 2 diabetes and prediabetes.
Metabolic syndrome — the cluster of abdominal obesity, high triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose — is present in a large proportion of people with MASLD. The two conditions are so closely linked that metabolic syndrome is often described as the systemic manifestation of the same process that drives hepatic fat accumulation. The Canadian Liver Foundation notes that type 2 diabetes substantially increases the risk of MASLD and of its progression to more advanced fibrosis.
Dietary factors, particularly high intake of refined carbohydrates, added sugars (especially fructose from sweetened beverages), and ultra-processed foods, drive hepatic fat accumulation independently of overall calorie intake. Fructose is metabolized almost exclusively in the liver and is particularly associated with hepatic fat in epidemiological data.
Visceral fat is the fat stored around abdominal organs rather than under the skin. It releases inflammatory signals and free fatty acids that further impair insulin signalling and accelerate liver fat deposition.
Alcohol-related vs. metabolic-associated fatty liver: These are distinct conditions with different drivers. Alcohol-related liver disease (ALD) is caused by chronic alcohol consumption. MASLD is driven by metabolic factors and occurs in people who drink little or no alcohol. However, alcohol use and metabolic liver disease can coexist, and even moderate alcohol accelerates fibrosis progression in people with established MASLD, per the AASLD 2023 Practice Guidance. Most hepatologists advise minimizing or eliminating alcohol once MASLD is diagnosed.
How fatty liver is diagnosed in Canada
Diagnosis typically follows a stepwise pathway:
Bloodwork is usually the first step. Routine liver enzymes — ALT (alanine aminotransferase), AST (aspartate aminotransferase), GGT (gamma-glutamyltransferase), and platelets — are ordered by family physicians as part of annual metabolic screens. Elevated ALT is the most common initial finding, though it can be normal even with significant hepatic fat. The FIB-4 index (a calculated score using age, ALT, AST, and platelets) is a validated non-invasive surrogate for fibrosis staging, per the AASLD 2023 guidance.
Abdominal ultrasound is typically the next step when enzymes are elevated or clinical risk factors are present. It can detect moderate to severe hepatic steatosis (fat content above roughly 20–30%) but cannot reliably detect mild steatosis or quantify fibrosis stage.
Transient elastography (FibroScan) uses low-frequency vibration to measure liver stiffness (a surrogate for fibrosis) and controlled attenuation parameter (CAP) to quantify hepatic fat. It is non-invasive, takes about 10 minutes, and has strong evidence for ruling out advanced fibrosis. In Canada, FibroScan is available through specialist referral on some provincial plans and privately through labs such as LifeLabs in several provinces.
Liver biopsy remains the gold standard for definitive fibrosis staging and grading of inflammatory activity (steatohepatitis), but it is invasive and reserved for cases where non-invasive assessment is inconclusive or where the diagnosis would alter clinical management. Most Canadians with MASLD will be staged non-invasively.
Treatment — lifestyle-first, then clinical escalation where appropriate
The AASLD 2023 Practice Guidance and the Canadian Liver Foundation's patient resources are consistent: lifestyle intervention is first-line treatment for MASLD at all stages.
Weight loss — the most powerful lever
The landmark evidence comes from Vilar-Gomez et al. (Gastroenterology, 2015), which biopsied 261 patients before and after a 52-week lifestyle program:
- ≥5% weight loss → steatohepatitis resolution in approximately 65% of patients
- ≥7% weight loss → steatohepatitis resolution in approximately 76%
- ≥10% weight loss → steatohepatitis resolution in approximately 90%; measurable fibrosis regression in approximately 45%
A 7–10% sustained weight reduction is the primary therapeutic target in every major clinical guideline for MASLD. The 2020 Canadian Adult Obesity Clinical Practice Guideline places this threshold at the centre of its metabolic comorbidity recommendations.
Mediterranean diet
Mediterranean-pattern eating — rich in vegetables, legumes, whole grains, olive oil, fish, and nuts, with limited red meat, processed food, and added sugar — has the strongest dietary evidence for reducing liver fat, independent of weight loss. A 2021 systematic review in Nutrients confirmed its association with reduced hepatic steatosis across multiple cohorts. The Canadian Liver Foundation recommends Mediterranean-pattern eating as part of MASLD management.
Physical activity
Both aerobic exercise and resistance training reduce hepatic fat, partly independently of weight loss. The AASLD guidance recommends at least 150–300 minutes of moderate-intensity aerobic activity per week plus resistance training twice weekly. Diabetes Canada's Clinical Practice Guidelines support the same activity targets for metabolic risk reduction.
Alcohol elimination
For people with MASLD, the evidence supports eliminating or minimizing alcohol entirely, regardless of how little was consumed before diagnosis. Even low-to-moderate alcohol intake accelerates fibrosis progression in the metabolically vulnerable liver.
Prescription options
Where lifestyle intervention alone has not achieved sufficient metabolic improvement, a licensed Canadian clinician may consider prescription options that are clinically appropriate for the individual's full metabolic picture. Any prescription approach is a complement to — not a replacement for — the lifestyle foundation. All decisions are individualized after a comprehensive assessment. Speak with your family physician or hepatologist about what the current evidence supports for your specific situation.
See if you qualify for a clinician-led program
The metabolic syndrome connection
MASLD and metabolic syndrome are deeply intertwined. The five components of metabolic syndrome — increased waist circumference, high triglycerides, low HDL cholesterol, elevated blood pressure, and elevated fasting glucose — are each independently associated with worse MASLD outcomes, and they cluster together precisely because they share the same root cause: insulin resistance.
Treating MASLD in isolation, focusing only on the liver without addressing the broader metabolic environment, misses the point. The lifestyle interventions that reverse metabolic syndrome (targeted weight loss, Mediterranean eating, physical activity) are the same ones that reverse MASLD. This is why a clinician-led metabolic program addresses both simultaneously.
Visceral fat deserves particular attention in this context. Fat stored around the abdominal organs is far more metabolically active than subcutaneous fat; it releases inflammatory cytokines and free fatty acids that drive both insulin resistance and direct hepatic fat deposition. Reducing visceral fat, which responds well to targeted weight loss and aerobic exercise, produces large improvements in liver markers relative to the overall weight lost.
Stages and prognosis — from simple steatosis to cirrhosis
MASLD exists on a spectrum, and prognosis is strongly stage-dependent:
| Stage | What it means | Liver prognosis |
|---|
| Simple steatosis (MASLD, F0) | Hepatic fat without significant inflammation or scarring | Near-normal liver-related mortality; cardiovascular risk is dominant |
| Steatohepatitis (MASH) | Fat plus inflammatory injury to liver cells | Elevated cardiovascular and liver mortality vs. simple steatosis |
| Fibrosis (F1–F3) | Progressive scarring; F3 is bridging fibrosis | All-cause mortality rises with stage; FIB-4 guides intervention intensity |
| Cirrhosis (F4) | Advanced, established scarring | Liver-related mortality rises sharply; surveillance for complications required |
The critical insight from the AASLD 2023 Practice Guidance is that fibrosis stage — not the diagnosis itself — is the strongest predictor of liver-related mortality. Simple steatosis, even untreated, carries a near-normal liver-related prognosis. The risk rises meaningfully at F2 and above.
At the population level, cardiovascular disease, not liver failure, is the leading cause of death in people with MASLD at all pre-cirrhosis stages. This makes cardiometabolic management (blood pressure, lipids, blood sugar, weight) the dominant life-expectancy lever. For a full look at prognosis by fibrosis stage, including the 7–10% weight-loss data and how it affects long-term mortality trajectories, see our fatty liver life expectancy guide.
When to see a Canadian clinician
See your family physician if:
- You have metabolic risk factors (abdominal weight, type 2 diabetes, elevated triglycerides, low HDL) and have not had liver enzymes checked recently
- A blood test shows elevated ALT, AST, or GGT without a clear explanation
- An imaging test mentions hepatic steatosis in the report
- You have a family history of liver disease
Ask for a specialist referral (hepatologist or gastroenterologist) if:
- Your FIB-4 score is ≥2.67, indicating likely advanced fibrosis per AASLD guidance
- Imaging or FibroScan suggests significant fibrosis or cirrhosis
- ALT is persistently elevated at more than three times the upper limit of normal
- You have signs of decompensation: jaundice, swollen abdomen, easy bruising, confusion
- A hepatocellular carcinoma screening question arises
Most Canadians with uncomplicated MASLD can begin the metabolic arc, the lifestyle changes that reverse hepatic fat, without waiting for specialist input. The sooner the metabolic environment improves, the more liver tissue there is to recover. If your family physician does not have the bandwidth to run a structured, monitored weight-loss program alongside you, medical weight loss programs in Canada are designed to fill that gap.
Start your eligibility check — it takes 3 minutes
The Canadian picture in plain numbers
- An estimated one in four Canadian adults has MASLD, per Canadian Liver Foundation data
- MASLD is the most common liver disease in Canada and globally
- Most cases at early stages are asymptomatic and diagnosed incidentally
- The Public Health Agency of Canada tracks obesity and type 2 diabetes — the twin drivers of MASLD — as rising national health priorities
- The AASLD estimates that MASH will surpass alcohol-related liver disease as the leading cause of liver transplantation in North America within this decade
These numbers reflect the scale of the public health opportunity. MASLD is largely preventable and, at early stages, largely reversible, and the levers that work are already well established in the evidence.
---
This article was prepared by the Cloudcure clinical content team and reflects the current AASLD 2023 Practice Guidance, Canadian Liver Foundation patient resources, and peer-reviewed evidence as of June 2026. It is for informational purposes only and does not constitute medical advice. Speak with a licensed Canadian clinician for assessment and personalized recommendations.